Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2295-2298

  Kaul, Sanjeev ^a   Christofalo, Barbara ^a   Raymond, Ralph H ^a   Stewart, Michael B ^a   Macleod, Catherine M ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAVUDINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FOOD INTAKE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE COUNT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

EID: 0031657439     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2295     Document Type: Article

References (39)

1. Berger P. B. 1996. Hope and caution: report from the XI International Conference on AIDS. Can. Med. Assoc. J. 155:717-721. (Comment.)
2. Blum, M. R., S. H. T. Liao, S. S. Good, and P. DeMiranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85 (Suppl. 2A):189-194.
3. Box, G. E. P., and D. R. Cox. 1982. Analysis of transformation. J. R. Stat. Soc. B. 265:211-252.
4. Browne, M. J., K. H. Mayer, S. B. D. Chafee, M. N. Dudley, M. R. Posner, S. M. Steinberg, K. K. Graham, S. M. Geletko, S. H. Zinner, S. L. Denman, L. M. Dunkle, S. Kaul, C. McLaren, G. Skowron, N. M. Kouttab, T. A. Kennedy, A. B. Weitberg, and G. A. Curt. 1993. 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J. Infect. Dis. 167:21-29.
5. Cretton, E. M., Z. Zhou, L. B. Kidd, H. M. McClure, S. Kaul, M. J. M. Hitchcock, and J.-P. Sommadossi. 1993. In vitro and in vivo disposition and metabolism of 3′-deoxy-2′,3′-didehydrothymidine. Antimicrob. Agents Chemother. 37:1816-1825.
6. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, and D. D. Richman for the AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
7. Davey, P., and S. Parker. 1992. Cost effectiveness of once-daily oral antimicrobial therapy. J. Clin. Pharmacol. 32:706-710.
8. Dudley, M. N., K. K. Graham, S. Kaul, S. Geletko, L. Dunkle, M. Browne, and K. Mayer. 1992. Pharmacokinetics of stavudine m patients with AIDS or AIDS-related complex. J. Infect. Dis. 166:480-485.
9. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 409-417. Marcel-Dekker, New York, N.Y.
10. Goebel, F. D. 1995. Combination therapy from a clinicians perspective. J. Acquired Immune Defic. Syndr. 10(Suppl. 1):S62-S68.
11. 3. Int. Conf. AIDS 11:287. (Abstract Tu.B. 2134.)
12. Griffith, B. P., H. Brett-Smith, G. Kim, J. W. Mellors, T. M. Chacko, R. B. Garner Y.-C. Chen, P. Alcabes, and G. Friedland. 1996. Effect of stavudine on human immunodeficiency virus type I virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J. Infect. Dis. 173:1252-1255.
13. Hartman, N. R., R. Yarchoan, J. M. Pluda, R. V. Thomas, K. S. Marczyk, S. Broder, and D. G. Johns. 1990. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin. Pharmacol. Ther. 47:647-654.
14. Hitchcock, M. J. M. 1991. 2′,3′-Didehydro-2′,3′-dideoxythymidine (D4T), an anti-HIV agent. Antivir. Chem. Chemother. 2:125-132.
15. Hollander, M., and D. A. Wolfe. 1973. Nonparametric statistical methods, p. 50-53. John Wiley, New York, N.Y.
16. Horton, C. M., M. N. Dudley, S. Kaul, K. H. Mayer, K. Squires, L. Dunkle, and R. Anderson. 1995. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob. Agents Chemother. 39:2309-2315.
17. Katlama C. Efficacy and tolerability of stavudine plus lamivudine in anti-retroviral-naive and previously treated patients with HIV infection. In press.
18. Katlama, C. A randomized trial to assess antiviral activity of two doses of stavudine (d4T) vs placebo in patients with early asymptomatic HIV-1 infection. In press.
19. Kaul, S., and K. A. Dandekar. 1993. Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys. Antimicrob. Agents Chemother. 37:1160-1162.
20. Kaul, S., B. Stouffer, V. Mummaneni, N. Turabi, S. Mantha, P. Jayatilak, and R. Barbhaiya. 1996. Specific radioimmunoassays for the measurement of stavudine in human plasma and urine. J. Pharm. Biomed. Anal. 15:165-174.
21. Kaul, S., V. Mummaneni, and R. H. Barbhaiya. 1995. Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations. Biopharm. Drug Dispos. 16:125-136.
22. Klecker, R. W., Jr., J. M. Collins, R. C. Yarchoan, R. Thomas, N. McAtee, S. Broder, and C. E. Myers. 1988. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J. Clin. Pharmacol. 28:837-842.
23. Kline, M. W., L. M. Dunkle, J. A. Church, J. C. Goldsmith, A. T. Harris, M. E. Federici, M. E. Schultze, L. Woods, D. F. Loewen, S. Kaul, A. Cross, V. L. Rutkiewicz, H. M. Rosenblatt, I. C. Hanson, and W. T. Shearer. 1995. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 96:247-252.
24. Knupp, C. A., R. Milbrath, and R. H. Barbhaiya. 1993. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J. Clin. Pharmacol. 33:568-573.
25. Larder, B. A., A. Kohli, S. Bloor, S. D. Kemp, P. R. Harrigan, R. T. Schooley, J. M. A. Lange, K. N. Pennington, M. H. St. Clair, and the Protocol 34,225-02 Collaborative Group. 1996. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. J. Virol. 70:5922-5929.
26. Lin, P.-F. H. Samanta, R. E. Rose, A. K. Patick, J. Trimble, C. M. Bechtold, D. R. Revie, N. C. Khan, M. E. Federici, H. Li, A. Lee, R. E. Anderson, and R. J. Colonno. 1994. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis. 170:1157-1164.
27. LoCaputo, S., P. Maggi, G. Buccoliero, M. Federico, G. Angarano, and G. Pastore. 1993. Antiretroviral therapy with zidovudine (AZT): evaluation of the compliance in a cohort of HIV+ patients. Int. Conf. AIDS 9:489. (Abstract PO-B26-2124.)
28. Lotterer, E., M. Ruhnke, M. Trautmann, R. Beyer, and F. E. Bauer. 1990. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur. J. Clin. Pharmacol. 40:305-308.
29. Medical Economics. 1997. Physicians' desk reference, 51st ed., p. 2981-2988. Medical Economics, Montvale, N.J.
30. Murray, H. W., K. E. Squires, W. Weiss, S. Sledz, H. S. Sacks, J. Hassett, A. Cross, R. E. Anderson, and L. M. Dunkle. 1995. Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. J. Infect. Dis. 171(Suppl. 2):S123-S130.
31. Petersen, E. A., C. H. Ramírez-Ronda, W. D. Hardy, R. Schwartz, H. S. Sacks, S. Follansbee, D. M. Petersen, A. Cross, R. E. Anderson, and L. M. Dunkle. 1995. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J. Infect. Dis. 171(Suppl. 2):S131-S139.
32. Pollard, R., D. Peterson, D. Hardy, L. Pedneault, V. Rutkiewicz, J. Pottage, R. Murphy, J. Gathe, G. Beall, J. Skovronski, A. Cross, and L. Dunkle. 1996. Stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects: antiviral effect and safety in an on-going pilot randomized double-blinded trial. Int. Conf. AIDS 11:225. (Abstract Th.B. 293.)
33. Pottage, J. C., C. A. Benson, B. E. Sha, P. A. Urbanski, and H. Kessler. 1995. Stavudine (d4T) in the therapy of patients with advanced AIDS and less than 50 CD4 cells Natl. Conf. Hum. Retroviruses Relat. Infect. 2:104.
34. Riegelman, S., and P. Collier. 1980. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. Pharmacokinet. Biopharm. 8:509-534.
35. Ruhnke, M., F. E. Bauer, M. Seifert, M. Trautmann, H. Hille, and P. Koeppe. 1993. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob. Agents Chemother. 37:2153-2158.
36. Sahai, J., K. Gallicano, G. Garber, I. McGilveray, N. Hawley-Foss N. Turgeon, and D. W. Cameron. 1992. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br. J. Clin. Pharmacol. 33:657-660.
37. Schuirmann, D. J. 1987. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15:657-680.
38. Skowron, G. 1995. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J. Infect. Dis. 171(Suppl. 2):S113-S117.
39. Unadkat, J. D., A. C. Collier, S. S. Crosby, D. Cummings, K. E. Opheim, and L. Corey. 1990. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 4:229-232.